Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Grows By 95.4%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 153,400 shares, an increase of 95.4% from the March 31st total of 78,500 shares. Based on an average daily volume of 648,100 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Avalo Therapeutics stock. Acadian Asset Management LLC bought a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 283,306 shares of the company’s stock, valued at approximately $34,000. Acadian Asset Management LLC owned 1.40% of Avalo Therapeutics at the end of the most recent quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Performance

NASDAQ AVTX traded up $1.00 on Friday, reaching $15.98. The stock had a trading volume of 73,802 shares, compared to its average volume of 537,467. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $1,130.40. The business’s 50-day moving average price is $9.19 and its 200 day moving average price is $13.46. The stock has a market cap of $16.46 million, a P/E ratio of -0.03 and a beta of 1.15.

Analysts Set New Price Targets

Separately, Oppenheimer upgraded Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, April 16th.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.